Information Provided By: 
Fly News Breaks for May 24, 2017
PCRX
May 24, 2017 | 10:16 EDT
Canaccord Genuity analyst Dewey Steadman says he's not concerned by the departure of Pacira Pharmaceuticals' president James Scibetta given the company's "deep bench of talent." He continues to view Pacira as "one of the most durable companies in specialty pharma." Steadman maintains a Buy rating on the shares with a $60 price target.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
